NCT07403435尚未招募2 期
Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable Esophageal Squamous Cell Carcinoma: a Single-center, Open-label Phase II Clinical Trial
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1 个研究点 分布在 1 个国家目标入组 22 人开始时间: 2026年2月15日最近更新:
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- pCR（Pathological Complete Response）
研究概览
简要总结
This study includes patients with resectable esophageal squamous cell carcinoma who will undergo local radiotherapy (PTV: 1.5Gy Bid, for 5 days), followed by neoadjuvant treatment with Serplulimab combined with cisplatin and paclitaxel for three cycles. Afterward, they will undergo surgery. Postoperatively, researchers will select adjuvant treatment plans based on the patients' conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histologically confirmed squamous cell carcinoma of the esophagus (ESCC) staged as cT1-2N+M0 and cT3NanyM0 (AJCC 8th edition);
- •Aged between 18-75 years;
- •ECOG performance status score of 0-1;
- •The following laboratory tests confirm that the bone marrow, liver and kidney functions meet the requirements for study participation
- •Hemoglobin ≥90g/L; ANC≥1.5×10^9/L;platelet count ≥100×10^9/L (patients must not have received blood transfusion or growth factor support within 14 days of blood sample collection);
- •ALT, AST ≤2.5*ULN; ALP ≤2.5*ULN;
- •Serum total bilirubin <1.5*ULN
- •Serum creatinine <1.5*ULN or estimated glomerular filtration rate (eGFR) ≥60ml/min/1.73m^2;
- •Serum albumin ≥30g/L;
- •INR or PT ≤1.5 *ULN, unless the patient is on anticoagulant therapy and the PT is within the expected therapeutic range; g. Activated partial thromboplastin time (APTT) ≤1.5 times ULN.
- •No severe concomitant diseases with a life expectancy of less than 5 years;
- •Voluntary and able to comply with the study protocol during the study period;
- •Provide written informed consent prior to entering the study, and the patient has been informed that they can withdraw from the study at any time without any loss.
排除标准
- •History of other malignancies in the past or concurrently, except for cured basal cell carcinoma of the skin and in situ cervical carcinoma; patients with small gastric stromal tumors and other tumors judged by the investigator to not affect the patient's life in the short term may be excluded;
- •Participation in other drug clinical trials within four weeks;
- •Patients with any active autoimmune disease or history of autoimmune disease (e.g., but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitaryitis, vasculitis, nephritis, hyperthyroidism; patients with vitiligo; asthma that was completely resolved in childhood and does not require any intervention in adulthood may be included; asthma requiring medical intervention with bronchodilators cannot be included);
- •Patients currently using immunosuppressants, or systemic corticosteroid therapy for immunosuppressive purposes (dose >10mg/day prednisone or other equivalent corticosteroids), and continued use within two weeks prior to enrollment;
- •Any active malignant tumor within two years, except for the specific cancer being studied in this trial and cured locally recurrent cancer (e.g., resected basal cell or squamous cell skin cancer, superficial bladder cancer, in situ cervical or breast carcinoma);
- •Patients with known central nervous system (CNS) metastasis or history of CNS metastasis at screening. For patients clinically suspected of CNS metastasis, a CT or MRI examination must be performed within 28 days before treatment to rule out CNS metastasis;
- •History of unstable angina; newly diagnosed angina within three months before screening or myocardial infarction event within six months before screening; arrhythmia (including QTcF: males ≥450 ms, females ≥470 ms) requiring long-term antiarrhythmic medication and New York Heart Association class ≥II heart failure;
- •Urine routine indicating proteinuria ≥++ and confirmed 24-hour urinary protein >1.0 g;
- •For female subjects: should be surgically sterilized, postmenopausal patients, or agree to use a medically recognized contraceptive method during the study treatment period and for six months after the end of the study treatment; serum or urine pregnancy test must be negative within seven days before study enrollment, and must not be lactating. For male subjects: should be surgically sterilized, or agree to use a medically recognized contraceptive method during the study treatment period and for six months after the end of the study treatment;
- •Patients who have undergone liver transplantation;
- •Infectious pneumonia, non-infectious pneumonia, interstitial pneumonia, and other patients requiring the use of corticosteroids;
- •History of chronic autoimmune diseases, such as systemic lupus erythematosus;
- •History of inflammatory bowel diseases such as ulcerative colitis, Crohn's disease, and history of chronic diarrheal diseases such as irritable bowel syndrome;
- •History of sarcoidosis or tuberculosis;
- •Active hepatitis B, hepatitis C, and HIV infection;
- •Untreated active syphilis;
- •History of substance abuse with psychotropic drugs and unable to quit or with psychiatric disorders;
- •Pleural effusion or ascites with clinical symptoms requiring clinical intervention;
- •History of immunodeficiency, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation;
- •According to the investigator's judgment, there are serious concomitant diseases that endanger patient safety or affect the patient's ability to complete the study.
研究组 & 干预措施
Treatment
Experimental
PTV:1.5Gy Bid,5 days Serplulimab (300mg) + Albumin-bound paclitaxel + Cisplatin/Carboplatin, Q3W, 3cycles
干预措施: Serplulimab (Drug)
结局指标
主要结局
pCR（Pathological Complete Response）
时间窗: within 14 working days after operation
Definition of pathology complete response is "no cancer cell, including lympho nodes"
次要结局
- MPR（Major Pathological Remission rate）(within 14 working days after operation)
- ORR（Objective Response Rate）(3-4 weeks after the last cycle of neoadjuvant treatment)
- Rate of R0 resection(within 14 working days after operation)
- EFS (Events Free Survival)(The date from the beginning of randomization to the date of first record. 5 years EFS)
- Safety assessment(From the first dose of study drug up to 30 days after last dose of any component of treatment or surgery or the initiation of subsequent anticancer therapy, whichever occurred first. Up to approximately 9 months.)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Serplulimab for Locally Advanced Cervical CancerCervical CancerNCT07340489Tianjin Medical University Cancer Institute and Hospital216
招募中
1 期
MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell CarcinomaNCT07359417UMC Utrecht30
招募中
2 期
Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell CarcinomaNCT07339488Chuangzhen Chen43
招募中
不适用
Balloon Dilation in Patients Undergoing Minimally Invasive Ivor Lewis Esophagectomy and Its Effect on Reducing DGCEDelayed Gastric Conduit Emtpying (DGCE)Minimally-invasive EsophagectomyNCT07355374University Hospital, Basel, Switzerland116
尚未招募
2 期
Stereotactic Body Radiation Therapy (SBRT) and Immunotherapy for Oligometastatic Esophageal CancerEsophageal CancerNCT07330583AHS Cancer Control Alberta22